CD8 T cells play an important role in controlling Ebola infection and in mediating vaccine-induced protective immunity, yet little is known about antigenic targets in Ebola that are recognized by CD8 T cells. Overlapping peptides were used to identify major histocompatibility complex class I-restricted epitopes in mice immunized with vectors encoding Ebola nucleoprotein (NP). CD8 T-cell responses were mapped to a H-2 d -restricted epitope (NP279 -288) and two H-2 b -restricted epitopes (NP44 -52 and NP288 -296). The identification of these epitopes will facilitate studies of immune correlates of protection and the evaluation of vaccine strategies in murine models of Ebola infection. D
Introduction
Ebola, a member of the filoviruses, causes severe hemorrhagic fever in humans and non-human primates. Four distinct species have been identified, the most pathogenic of which, Ebola Zaire, has a fatality rate of approximately 85%. Throughout the previous 10 years, outbreaks of Ebola have occurred regularly in several central African countries, such as Gabon and Uganda (Arthur, 2002) . Often, spread has occurred through nosocomial inoculation including many infections in primary care givers. In addition, the potential use of Ebola for the purposes of bioterrorism highlights the need for methods of rapidly controlling its spread and protecting uninfected individuals, particularly in certain sections of the population such as health workers. There are currently no effective treatments or vaccines available for Ebola. Recent studies, however, have shown the potential of recombinant vaccination strategies to protect both small animals and non-human primates from challenge with infectious Ebola (Hart, 2003; Sullivan et al., 2000) . Further development of effective vaccines depends on understanding the roles that various immune effectors play in protective immunity and identifying protective antigens that are recognized by these effector cells. A major impediment to the study of T-cell responses against Ebola concerns the complexities of applying immunological techniques to BSL-4 conditions. To overcome these difficulties, we have employed a heterologous prime/boost strategy using recombinant vaccine vectors expressing Ebola proteins to induce high levels of Ebola-specific T cells and screen for T-cell epitopes using overlapping peptide libraries. Here, we report our detailed mapping of H-2 b -and H-2 d -restricted CD8 Tcell epitopes from Ebola nucleoprotein (NP) and a comparative analysis of several heterologous prime/boost vaccine strategies. These results provide critical information for analyzing T-cell responses in murine models of infection with mouse-adapted Ebola that has been used as the first step in testing experimental Ebola vaccines.
Results

Mapping of H-2 d -restricted CD8 T-cell epitopes in Ebola nucleoprotein
Alphavirus and DNA-based vaccines expressing NP have been shown to be protective against Ebola challenge in animal models (Pushko et al., 2001; Vanderzanden et al., 1998; Wilson and Hart, 2001 ). Adoptive transfer of T-cell subsets strongly implicates CD8 T cells in this protection (Wilson and Hart, 2001) .
To identify CD8 T-cell epitopes in Ebola NP, a DNA prime with double heterologous boost strategy was initially employed to maximize the likelihood of obtaining a strong cellular immune response. BALB/c mice were primed with DNA expressing Ebola Zaire Mayinga NP (DNA-NP), followed by boosting with replication-deficient adenovirus encoding NP (Ad-NP), and finally with recombinant Listeria monocytogenes expressing NP (rLM-NP). Splenocytes were harvested 7 days after the final immunization and re-stimulated in vitro with pools of overlapping peptides corresponding to NP, followed by intracellular interferon g (IFN-g) staining (Fig. 1A) . Of 24 peptide pools screened, only pools #8 and #17, as well as a positive control of the endogenous rLM specific epitope, LLO91 -99, showed specific stimulation of an IFN-g response in CD8 T cells, while the remaining pools, as exemplified by pool #7, showed no response ( Fig. 1A and data not shown).
Peptides were arrayed (see Materials and methods) so that each peptide was represented in only two pools, allowing easy identification of the candidate peptide by crossreferencing positives (Maecker et al., 2001; van der Most et al., 2002) . The common peptide between pools #8 and #17 is NP276 -291 (EVNSFKAALSSLAAKHG) and this peptide was able to stimulate a population of CD8 T cells from immunized mice to produce IFN-g, while other individual peptides from either pool #8 or #17, such as peptide NP96 -111, were not (Fig. 1B and data not shown) . To finely map the epitope within this peptide, the NP sequence was analyzed using the SYFPEITHI algorithm (Rammensee et al., 1999) 
d -restricted peptides were predicted, but the only one of which to fall within NP276 -291 was NP279 -288 (SFKAALSSLA). NP279 - 288, together with a negative control corresponding to the N terminus of peptide #56 (NP276 -285; EVNSFKAALS), were synthesized and tested for their ability to stimulate splenic CD8 T cells from immunized mice (Fig. 1C) . The nonamer peptide NP279 -288 and the parental 16-mer peptide NP276 -291 were positive in inducing a population (f4.5%) of CD8 T cells to produce IFN-g while the control peptide, NP276 -285, was not. Subsequent testing of NP279 -288 confirmed its role as a strong CD8 T-cell epitope elicited by NP, but not control, immunizations (Fig. 1D) . A DNA-NP prime followed by an Ad-NP boost was sufficient to stimulate a strong CD8 T-cell response to NP279 -288 while a control of DNA plasmid encoding GFP followed by an Ad-GFP boost did not induce a NP279 -288-specific response (Fig. 1D) . Mapping of the minimal epitope of NP279 -288 represents the first H-2 d -restricted (and by computational analysis K d -restricted) peptide described for Ebola NP.
Mapping of H-2 b -restricted CD8 T-cell epitopes in Ebola nucleoprotein
Using the same strategy, two H-2 b -restricted epitopes were identified in C57BL/6 mice ( Fig. 2 ). C57BL/6 mice were immunized in an identical fashion to the BALB/c mice, with DNA-NP, Ad-NP, and rLM-NP inoculations. Splenocytes were stimulated with peptide pools and positive IFN-g T-cell responses were noted with peptide pools #6, #9, #13, and #19 ( Fig. 2A) . Positive results in these four peptide pools corresponded to four potential peptides NP26 -41, NP41 -56, NP386 -401, and NP401 -416. While NP26 -41 and NP401 -416 gave results similar to the no peptide control, NP41 -56 and NP386 -401 were strongly positive when tested in isolation (Fig. 2B ). NP41 -56 was a shared peptide in pools #9 and #13, while NP386 -401 was contained in both pools #6 and #19. Thus, it was likely that these peptides comprised two separate epitopes within NP. Using SYFPEITHI (Rammensee et al., 1999) , a H-2D brestricted epitope NP44 -52 (YQVNNLEEI) was predicted to be present within the NP41 -56 sequence and this was confirmed experimentally as the NP44 -52 nonameric peptide was able to stimulate IFN-g-producing CD8 T cells in splenocytes from immunized mice (Fig. 2C ). NP44-52 corresponds to a previously described H-2 b epitope in NP, NP43 -53 (Wilson and Hart, 2001 ), although our result further mapped this epitope to a minimal nonamer NP44 -52. Interestingly, no peptides within NP386 -401 were predicted to have strong binding affinity for H-2K b or H-2D b by the SYFPEITHI algorithm. Two peptides (NP388-396 and NP393 -402) within NP386 -401, however, had a low predicted binding affinity for H-2D b . NP388 -396 (FQQTNAMVT) tested positive experimentally (Fig. 2C) , while the second peptide (AMVTLRKERL; NP393 -402) was negative in stimulating CD8 T cells from NP-immunized mice (Fig. 2C) . Thus, NP388 -396 represents a novel H-2 b -restricted epitope in Ebola NP. NP43 -53 gave a stronger response than NP388 -396 with approximately 8.5% and 2.2% of CD8 T cells responding to these peptides, respectively (Fig. 2C) . Also, in all assays using the 16-mer peptides encompassing these epitopes (NP41 -56 and NP386 -401, respectively), a stronger response to the NP44 -52 epitope was observed. Thus, NP44 -52 may represent the immunodominant epitope in NP-immunized C57BL/6 mice.
Optimization of immunization strategies
Our initial strategy utilized a triple immunization protocol involving DNA-NP-prime/Ad-NP boost/rLM-NP boost to facilitate generation of Ebola-specific T cells for identification of T-cell epitopes. We next tested various prime/ boost immunization strategies for inducing NP279 -288-specific CD8 T cells in BALB/c mice (Fig. 3) . Single immunizations with any of the three immunogens led to poor T-cell responses (Fig. 3A) . Homologous prime/boost with Ad-NP or rLM-NP were less effective than heterologous prime/boost with these two vectors, presumably due to immune responses against the vector during the boost (Schneider et al., 1999) . However, homologous prime/boost with Ad-NP did induce a strong CD8 T-cell response that was much higher than that by homologous prime/boost with rLM-NP (Fig. 3A) . Interestingly, rLM-NP was not very effective in boosting a DNA-NP prime but was effective in boosting an Ad-NP prime, while Ad-NP was very effective in boosting either a DNA-NP or rLM-NP prime. The highest response came from heterologous prime with rLM-NP followed by boost with Ad-NP.
In the above prime/boost regimens, the boosts were given 3 weeks after initial primes as it has been shown that resting the immune system for an extended period allows for better boost. Due to the nature of filovirus infection, however, a long immunization protocol is not desirable because it is unlikely that large populations will be immunized prophylactically against Ebola. Rather, a short protocol for stimulating fast and effective protective immunity is needed in situations without pre-existing immunity to control the spread of a rapidly developing epidemic or bioterror attack. We thus tested heterologous prime/boost immunizations with a shorter interval (1 week) to optimize the immunization strategy in terms of rapidity (Fig. 3B) . Boosting with Ad-NP only 1 week after DNA-NP prime was sufficient to stimulate a strong antiviral response to a level comparable to those when boost was given more than 3 weeks after prime. As seen before, boosting DNA-NP prime with rLM-NP was not effective. On the other hand, quick prime/boost regimens using the Ad-NP/rLM-NP or rLM-NP/Ad-NP were effective although the responses were slightly lower than those induced by immunizations with a 3-week interval. It will be interesting to see if a DNA prime followed rapidly by a single boost may be sufficient to stimulate some level of protection in small animal models, and whether this short time-frame regimen would also work at stimulating at least CD8 T-cell responses in primates and human.
Discussion
Ebola represents an emerging potential threat, both in terms of sporadic epidemics and possible bioterrorism. Currently no effective therapies or vaccines exist and relatively little is know about the pathogenic nature of the virus. In particular, it is not clear why the virus is so pathogenic in many cases, yet asymptomatic in others (Leroy et al., 2000 (Leroy et al., , 2001 , and whether this is due to differences in the immune response to the virus, especially CTL responses. To study more closely cellular immune responses in animal models, MHC-restricted CD8 T-cell epitopes need to be identified. In this study, we have identified two novel epitopes, H-2 b -restricted NP388-396 and H-2 d -restricted NP279 -288, confirmed a previously H-2 b -restricted NP43-53 epitope (Wilson and Hart, 2001 ) and further mapped this epitope to a minimal NP44 -52 nonamer. NP338 -396, NP44 -52, and NP279 -288 epitopes are predicted, using the SYFPEITHI algorithm, to be presented by H-2D b , H-2D b , and H-2K d , respectively. Examination of the Ebola NP sequences reveals that the three epitopes are conserved between different strains of Ebola Zaire, including a mouse-adapted strain (Bray et al., 1999) . Thus, these epitopes will enable the further detailed study of the CD8 T-cell response to Ebola infection in mice, including potential perturbation of the immune response by Ebola-encoded determinants. One of the most striking aspects of Ebola pathology is immune suppression, including lymphocyte depletion and suppression of T-cell proliferation as well as an apparent lack of inflammatory infiltrates in target organs (Geisbert et al., 2000) . Humoral immune responses can also be defective, with Ebola-specific IgG often entirely absent in patients in whom infection proved fatal (Baize et al., 1999) . Of particular interest are the differences in immune responses between individuals where infection results in either fatality or asymptomatic infection (Leroy et al., 2000 (Leroy et al., , 2001 . At least one determinant of this is likely to be VP35, which acts as a type I interferon antagonist (Basler et al., 2000) . Other viral determinants, including the glycoprotein (GP) have also been suggested to play a role in the perturbation of the immune response, including the down-regulation of MHC and accessory molecules (Simmons et al., 2002) and the ability to bind to DC-SIGN on dendritic cells (Simmons et al., 2003) , thus potentially inhibiting DC-SIGN/ICAM-3-mediated interactions between dendritic cells and T cells. The ability to determine specific T-cell responses to Ebola in mice using these epitopes will aid in the investigation of such parameters of viral pathogenesis.
The studies in murine models represent a necessary first step in the development of potential vaccine strategies that can then be further tested in primates and humans. The results of our study provide critical information for studying immune correlates of protection and evaluating effectivity of vaccine strategies in murine models of Ebola infection. The methods described here for mapping and analysis of T-cell responses directed against Ebola NP protein can also be easily adapted to study other Ebola proteins and in other species such as primates and humans.
Materials and methods
Plasmids and vectors
Ebola Zaire Mayinga-derived NP (Sanchez et al., 1989) was cloned in pAd-Track CMV (He et al., 1998) as a DNA vaccine (DNA-NP). Plasmid DNA was purified using Qiagen megaprep kits for administration into animals. Recombinant adenovirus expressing NP and GFP from separate CMV promoters (Ad-NP) was generated from pAd-Track CMV/NP using homologous recombination in bacteria (He et al., 1998) , amplified in 293f cells and purified using Adeno-X columns (BD Biosciences, San Jose, CA). Virus was titered on 293T cells and numbers of green fluorescent cells quantified by flow cytometry to estimate a green fluorescent unit per milliliter (GFU/ml) titer. Controls expressing only GFP (Ad-GFP) were generated in the same way. Recombinant L. monocytogenes (rLM) strains were constructed as previously described in a wild-type strain (10403S, Shen et al., 1998) . Three strains were constructed that express the C-terminal half of Ebola nucleoprotein (NP) epitope (XFL601), the N-terminal half of Ebola NP (XFL602), or the full length of Ebola NP (XFL603). The rLM strains were greatly attenuated due to expression of Ebola NP. A cocktail containing an equal mixture of XFL601, XFL602, and XFL603 was used for immunization (for clarity, the cocktail is referred to as rLM-NP).
Peptides
Peptides derived from the Ebola Zaire Mayinga NP sequence were synthesized as 16-mers with 11-amino-acid overlap with the preceding peptide (Mimotopes, Victoria, Australia) and dissolved in DMSO at approximately 80 Ag/ ml. Pools of peptides containing 10 -12 peptides at a final concentration of 1 Ag/ml each were aliquoted such that each peptide was represented twice and thus results could be cross-referenced and individual peptides identified (Maecker et al., 2001; van der Most et al., 2002) . Shorter peptides corresponding to potential epitopes were obtained from Invitrogen (Carlsbad, CA) or Bio-Synthesis Inc. (Lewisville, TX) and solubilized in DMSO (80 Ag/ml). Peptides were used at 0.1 Ag/ml and DMSO concentrations were kept below 0.1% (v/v) in all final assay mixtures.
Animal experiments
C57BL/6 and BALB/C mice (6 -8 weeks old) were purchased from the National Cancer Institute (Frederick, MD). Mice were immunized with 100 Ag DNA plasmid (DNA-NP or DNA-GFP) via bilateral injections of 50 Al into the anterior tibial muscles, i.p. with 2 Â 10 8 GFU Adenovirus (Ad-NP or Ad-GFP), and i.v. with rLM-NP (1 Â 10 7 CFU for BALB/c and 1 Â 10 8 CFU for C57BL/6 mice). All mice were maintained in accordance with Institutional Animal Care and Use Committee-approved protocols at the University Laboratory Animal Resources of the University of Pennsylvania School of Medicine (Philadelphia, PA).
Intracellular IFN-c staining
Splenocytes were cultured at 37 jC for 5 h in RPMI 1640 supplemented with 50 U/ml recombinant human IL-2, monensin (1 Al/ml), and with or without 1 AM synthetic peptide. Cells were stained with mAbs a-CD8 PerCP (clone 53-6.7) and mAbsa-CD44 (clone IM7) or a-CD11a (LFA-1, clone 2D7) in 1% BSA/PBS (w/v). Splenocytes were then permeabilized with a Cytofix/Cytoperm kit, and stained with mAba-IFN-g (clone XMG1.2) and a-TNF-a (clone MP6-Xt22). After staining, cells were fixed with 2% paraformaldehyde/PBS (w/v), and acquired with a FACSCalibur flow cytometer (BD Biosciences). Data was analyzed using Flow-Jo (Tree-Star, San Carlos, CA).
